Company Overview We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 ( PDE4 ) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease ( IBD ), including ulcerative colitis (…
Negative free cash flow of -$11M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$24M
▼ -16.2% YoY
Op. Margin
—
ROIC
-31.88%
▲ +102.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$12M
▲ +11.0% YoY
Op. Cash Flow (TTM)
-$12M
▲ +11.0% YoY
Net Debt
-$133M
Net Cash Position
Cash & Equiv.
$133M
Continue Research